Pharmaceutical Working Group Annual Report 2023 Go back »


The Pharmaceutical Working Group represents nearly 40 international pharmaceutical manufacturing companies operating in China. The working group engages in a constructive dialogue with government agencies at the national, provincial and local levels, and shares its expertise and international best practices with the Chinese authorities. In particular, the working group has established a sound communication channel with the Chinese medical authorities and regulators. It encourages government policies that support the creation of a sustainable environment, which fosters innovation and the healthy growth of the pharmaceutical industry as a whole while improving patients’ access to affordable, innovative and high-quality medicines. The Pharmaceutical Working Group also offers recommendations based on experience accumulated during decades of healthcare reform in European countries that may further support the development of China’s healthcare system.

Related documents

Intellectual Property Rights Working Group Annual Report 2023

Intellectual Property Right Working Group Position Paper 2020/2021 - 知识产权工作组建议书2020/2021

Annual Working Group Report 2019 - Intellectual Property Rights Working Group